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AbstrACt
Objectives Within the Emirati population, risk factors and 
genetic predisposition to diabetic kidney disease (DKD) 
have not yet been investigated. The aim of this research 
was to determine potential clinical, laboratory and reported 
genetic loci as risk factors for DKD.
research design and methods Four hundred and ninety 
unrelated Emirati nationals with type 2 diabetes mellitus 
(T2DM) were recruited with and without DKD, and clinical 
and laboratory data were obtained. Following adjustments 
for possible confounders, a logistic regression model was 
developed to test the associations of 63 single nucleotide 
polymorphisms (SNPs) in 43 genetic loci with DKD (145 
patients with DKD and 265 without DKD). Linear regression 
models, adjusted for age and gender, were then used to 
study the genetic associations of five renal function traits, 
including 83 SNPs with albumin-to-creatinine ratio, 92 
SNPs with vitamin D (25-OH cholecalciferol), 288 SNPs 
with estimated glomerular filtration rate (eGFR), 363 SNPs 
with serum creatinine and 73 SNPs with blood urea.
results Patients with DKD, as compared with those 
without the disease, were mostly men (52%vs38% for 
controls), older (67vs59 years) and had significant rates 
of hypertension and dyslipidaemia. Furthermore, patients 
with DKD had T2DM for a longer duration of time (16vs10 
years), which in an additive manner was the single 
factor that significantly contributed to the development 
of DKD (p=0.02, OR=3.12, 95% CI 1.21 to 8.02). Among 
the replicated associations of the genetic loci with 
different renal function traits, the most notable included 
SHROOM3 with levels of serum creatinine, eGFR and DKD 
(P
adjusted=0.04, OR=1.46); CASR, GC and CYP2R1 with 
vitamin D levels; as well as WDR72 with serum creatinine 
and eGFR levels.
Conclusions Associations were found between several 
genetic loci and risk markers for DKD, which may 
influence kidney function traits and DKD in a population of 
Arab ancestry.
IntrOduCtIOn 
This overall dramatic worldwide increase in 
the number of people with diabetes has had 
a major impact on the increasing incidence 
and prevalence of diabetic kidney disease 
(DKD) as one of the most frequent compli-
cations of both types of diabetes. Globally, the 
prevalence of chronic kidney disease (CKD) 
among adults in the general population is 
reported to be around 10%.1 However, 20% 
of adults with type 2 diabetes mellitus (T2DM) 
are expected to develop DKD based on esti-
mated glomerular filtration rate (eGFR) 
measurements (<60 mL/min/1.73 m2), while 
the number reaches 30%–50% based on 
the urinary albumin excretion levels.1 This 
considerable variation is due to variances in 
settings, geographical area and ethnicity.2 
Overall, the risk of DKD in T2DM is approx-
imately 2% per year.3 In the Arab world, the 
prevalence of DKD is also highly variable 
(10.8%–61.2%)%) depending on the study 
design, population, sample selection, race, 
age, sex, as well as diagnostic criteria among 
other factors.4 Meta-analysis has shown that 
DKD is the leading cause of end-stage renal 
disease (ESRD) in the Gulf Cooperation 
Council (GCC) with a prevalence of ~17%.5 
Patients with ESRD have a 20% annual 
strengths and limitations of this study
 ► This cross-sectional study to determine the clini-
cal, laboratory and genetic associations of diabetic 
kidney disease (DKD) and renal function traits in a 
sample of patients with type 2 diabetes mellitus was 
the first of its kind in a population of Arab ancestry 
from the United Arab Emirates.
 ► A limitation inherent to this study was that the anal-
yses carried out did not include treatment modalities 
due to patients having multiple conditions and treat-
ments, which made the models largely unstable and 
difficult to interpret.
 ► Current analyses of the DKD genetic association had 
a statistical power of ~57%, suggesting that a larger 
population sample across the Middle East is required 
to discover novel clinical and genetic predisposition 
to DKD in the region with better statistical power.
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mortality rate, which is higher than the rate for many 
solid cancers.6 In addition to increasing the risk of cardio-
vascular morbidity and mortality7 8, DKD is reported to be 
the single strongest predictor of mortality in patients with 
diabetes,9 with a 5-year survival in the range of 30%.10 
The current trend suggests that the prevalence of DKD 
will continue to increase worldwide, leading to increased 
morbidity and mortality and imposing significant socio-
economic burdens on global healthcare systems.11 A 
thorough literature search reveals that there remains a 
wide knowledge gap related to the understanding of risk 
factors and pathophysiological mechanisms associated 
with DKD, especially in the GCC and Middle East. Since 
ESRD can only be treated with highly invasive and costly 
procedures, such as dialysis or kidney transplantation, 
better knowledge of genetic, clinical and epidemiological 
factors associated with DKD is required to allow for timely 
and more effective treatment options.
In clinical practice, renal function is assessed using a 
number of tests that are reported to have high heritability 
rates.12 This indicates that genetic factors contribute 
significantly to interindividual variance in kidney func-
tion, and hence, to the susceptibility to CKD and related 
conditions. Thus far, several genetic loci have been linked 
to DKD, CKD and renal function traits in adults13–24 as 
well as children.25 However, in comparison with other 
diseases, including T2DM and other cardiometabolic 
disorders, studies of kidney disease and kidney function 
traits are largely insufficient and inconclusive. In spite of 
efforts to describe novel biomarkers for DKD, currently no 
tested candidates outperform albumin. A recent report 
by Saulnier et al suggests that three serum biomarkers 
(midregional-proadrenomedullin, soluble tumour 
necrosis factor receptor 1 and N-terminal prohormone 
brain natriuretic peptide) can improve risk prediction of 
the loss of renal function in patients with T2DM, in addi-
tion to the established risk factors for DKD such as age, 
sex, diabetes duration, HbA1c, blood pressure, baseline 
eGFR and albumin-to-creatinine ratio.26 However, issues 
such as whether the levels of these markers are affected 
by genetic variations, and whether the encoding genes 
contribute to DKD development and progress need 
further investigation.
The United Arab Emirates (UAE) is among the coun-
tries with the highest prevalence rates of T2DM, obesity 
and cardiovascular disease.27 28 AlSafar and colleagues 
have recently reported that approximately 80% of patients 
with T2DM within UAE present with at least one compli-
cation associated with T2DM, including kidney disease 
(approximately 6%).29 Furthermore, there is increasing 
evidence suggesting that the genome structure of individ-
uals of Arabic descent is different from individuals from 
other populations.30 Despite the high prevalence rate of 
DKD in the UAE, there have been no investigations up to 
date of the genetic associations of chronic kidney condi-
tions and kidney functions, particularly as associated with 
T2DM. Therefore, the current work aimed to investigate 
the clinical and laboratory variables linked to DKD in a 
T2DM Emirati population and to study the associations 
of the reported genetic loci linked to different renal func-
tion tests in CKD and DKD.
MAterIAls And MethOds
study type and subjects
This work describes a cross-sectional study of Emirati 
patients from the city of Abu Dhabi. The demographic 
information and clinical data for the participants are 
presented in tables 1 and 2. Four hundred and ninety 
(n=490) patients with T2DM were included in the study, 
Table 1 Baseline data of tested traits and tested SNPs
Trait
Mean±SD or 
quartiles
N of subjects 
(male/female)
N of SNPs 
reported* N of SNPs tested* Covariates
ACR (mg/mmol) 1.05/3.9/12.7† 115 (56/59) 331 83 Age and gender.
Vitamin D (ng/mL) 63.7±27.8 328 (146/182) 442 92 Age and gender.
eGFR (ml/
min/1.73 m2)
81.5±28.5 395 (172/223) 1478 288 Age and gender.
Serum creatinine 
(µmol/L)
60/74/95.8† 474 (246/228) 1792 363 Age and gender.
Blood urea 
(mmol/L)
6.4±5.4 450 (263/214) 446 73 Age and gender.
Diabetic kidney 
disease
With: 145.
Without: 265.
288 63 Age, gender, 
hypertension, T2DM 
duration and eGFR 
levels.
*Reported means the total number of SNPs found in the search in the literature and tested means the actual number of SNPs found from the 
reported SNPs and used for the analyses in this study for each corresponding trait.
†For the albumin:creatinine ratio (ACR) and creatinine analyses, summary statistics indicated by 25th/50th/75th quartiles and not as 
mean±SD because their distributions are skewed.
eGFR, estimated glomerular filtration rate; SNPs, single nucleotide polymorphisms; T2DM, type 2 diabetes mellitus.
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with 145 diagnosed with DKD. The participants were 
recruited from Sheikh Khalifa Medical City and Mafraq 
Hospital, major tertiary hospitals in Abu Dhabi, UAE. All 
subjects were UAE born and of Arabian descent.
Patient and public involvement
The study was designed because T2DM, along with its 
multiorgan complications, is a major health challenge 
in the UAE with increasingly growing public interest. 
However, patients and the public at large were not 
involved in defining the research questions, analyses, 
interpretation or dissemination of the results.
Clinical variables and laboratory data
Various clinical and laboratory measures were collected/
assessed during the hospital visits. Blood pressure was 
taken on two different occasions. Hypertension was 
defined as systolic blood pressure ≥140 mm Hg, diastolic 
blood pressure ≥90 mm Hg or if the patients were taking 
any antihypertensive medications. Dyslipidaemia was 
either reported based on clinical records of the partic-
ipants or diagnosed as previously indicated.31 The pres-
ence of T2DM was confirmed by a qualified physician 
based on criteria outlined by the WHO.32 Trained nurses 
measured the height and weight of each participant using 
a calibrated wall-mounted stadiometer and a weight scale, 
respectively. Body mass index was calculated as the weight 
in kilograms divided by the square of the height in metres 
(kg/m2).
diabetic kidney disease
DKD was defined as either decreased levels of eGFResti-
mated glomerular filtration rate (<60 mL/min/1.73 m2) 
with or without renal damage over a period of at least 
3 months,33 or based on an albumin-to-creatinine 
ratio ≥30 mg/g, or proteinuria >500 mg over a 24-hour 
period in the setting of T2DM and/or abnormalities, 
as assessed by imaging or histology.34 eGFR was calcu-
lated according to CKD-EPI Creatinine Equation.35 
Table 2 Demographic, clinical and laboratory characteristics of T2DM patients with or without kidney disease
Type of variables Variable DKD No DKD P value*
Demographic variables
Gender: female† 70 (48.3) 165 (62.3) 0.006
Age (years) 67.0±10.4 58.6±10.6 <0.0001
Clinical variables
Clinical hypertension † 96.6 74.3 <0.0001
Dyslipidaemia † 95.2 90.9 0.17
Smoking history † 32.4 24.2 0.07
Diabetes duration (years) 16.0±9.2 10.1±7.3 <0.0001
BMI (kg/m2) 31.3±6.0 32.5±6.3 0.078
Laboratory variables
Glycaemic indices Hemoglobin A1c (%) 7.7±1.5 7.8±1.7 0.63
Fasting plasma glucose (mmol/L) 8.3±3.1 8.9±3.8 0.43
Random blood glucose (mmol/L) 9.1±3.9 9.5±4.3 0.34
Lipids profile Total cholesterol (mmol/L) 3.7±1.0 4.0±1.1 0.003
Triglyceride (mmol/L) 1.5±0.8 1.6±0.8 0.25
HDL-cholesterol (mmol/L) 1.2±0.6 1.2±0.5 0.45
LDL-cholesterol (mmol/L) 1.9±0.8 2.1±0.9 0.01
Renal function indices Albumin:creatinine ratio (mg/mmol) ‡ 3.3/10.1/69.6 0.8/2.2/9.0 0.0001
Vitamin D (nmol/L) 62.9±28.4 65.3±26.8 0.48
eGFR (mL/min/1.73 m2) 57.5±27.7 96.1±17.3 <0.0001
Creatinine (µmol/L) ‡ 82/111/146 55/64/76 <0.0001
Urea (mmol/L) 9.7±8.3 4.7±1.5 <0.0001
*P value for continuous data, calculated using two-sided t-test except for albumin:creatinine ratio and creatinine where it is for Wilcoxon rank-
sum (Mann-Whitney) test. P value for percentage data calculated using Pearson χ2 test with exception of hypertension and dyslipidaemia 
where Fisher’s exact test was used.
† Proportional data shown as number of positive outcome and its percentage. All remaining continuous data shown as mean±SD except 
albumin:creatinine ratio and creatinine.
‡For the albumin:creatinine ratio and creatinine analyses, summary statistics indicated by 25th/50th/75 quartiles and not as mean±SD 
because their distributions are highly skewed.
BMI, body mass index; DKD, diabetic kidney disease; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, high-
density lipoprotein; T2DM, type 2 diabetes mellitus.
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Accordingly, 145 patients with TD2M were identified with 
DKD, while 265 were identified as disease free (tables 1 
and 2). The remaining 80 patients could not be classified 
with or without DKD at the time of the study and were 
excluded from subsequent analyses.
selection of snPs
Genetic investigation in this study followed the candi-
date gene approach.36 The SNPs tested for each trait are 
summarised in table 1. These SNPs were selected from 
a recent Genome Wide Association Study (GWAS) that 
was intended to determine the genetic associations of 
T2DM in the UAE population towards establishing the 
Emirates Family Registry for T2DM.27 The GWAS was 
performed for 490 samples with T2DM and 450 healthy 
controls using the Infinium Omni5ExomeHuman chip 
(Illumina, San Diego, California, USA). To select the 
SNPs associated with the kidney function traits included 
in the study (blood urea, serum creatinine, eGFR values, 
albumin-to-creatinine ratio and vitamin D levels) as well 
as DKD, various search engines and data bases including 
PubMed, Google Scholar, the GWAS catalogue (https://
www. ebi. ac. uk/ gwas/ home), the Phenolyzer database 
(http:// phenolyzer. wglab. org/), the infinome genome 
interpretation platform (https://www. infino. me/) and 
the GWAS Central database (http://www. gwascentral. 
org/) were consulted.
Our search strategy consisted of identifying reported 
SNPs that cleared the GWAS significance level and were 
found in our GWAS data. If the original signal SNP was 
missing from the GWAS data, we searched for a possible 
proxy SNP using the concept of linkage disequilibrium 
(LD). This typically indicates a non-random association 
of alleles at different genetic loci in a given population 
and their tendency to be inherited as a block (mathemat-
ical values r2 and D′>0.8 indicates high LD). Proxy SNPs 
were selected using the SNAP database for SNP Anno-
tation and Proxy Search (http:// archive. broadinstitute. 
org/ mpg/ snap/ ldsearch. php).
All SNPs located within and flanking genes that have 
been previously reported in association with CKD and 
DKD were included. In total, 43 genetic loci were iden-
tified as linked to CKD, DKD or a decline in renal func-
tion. Specifically, the gene loci comprised: ACACB, ACE, 
ACTN4, ADIPOQ, ADM, AFF3, AGTR1, APOL1, CARS-
CNDP1, CNDP2, CPS1, CPVL, CPVL, CHN2, CYBA-ELMO1, 
ENPP1, ERBB4, FABP2, FRMD3, GLUT1, IRS2, MYO16, 
LIMK2, MCTP2, MYO16, MYH9, NCALD, NCK1, NOS3, 
NPHS1, NPHS2, NPPB, PLCE1, PPARγ2, PVT1, RAGE, 
RGMA, RPS12, SFI1, SHROOM3, TMEM22, TNFRSF1A 
and TRPC6.
statistical modelling and analyses
Continuous variables were presented as mean±SD or 
lower/median and upper quartiles where the distribu-
tions were highly skewed. Vitamin D and eGFR levels 
were normally distributed. However, urea levels, creat-
inine levels and albumin-to-creatinine ratio data were 
converted to normal distributions using natural log 
transformation. The associations of trait values or their 
natural logs (if transformed) were tested with SNPs 
using linear regression models, which included age 
and gender as covariates using PLINK software V.1.07 
(http:// zzz. bwh. harvard. edu/ plink/). The same soft-
ware was used for counting allele frequencies and 
testing the quality control (QC) variables. Any SNPs with 
minor allele frequency (MAF) <0.05, and >5% missing 
genotype rate, or those that failed the Hardy-Weinberg 
equilibrium (HWE) test at the 0.001 were excluded. 
HWE is considered as an important QC test for genetic 
association studies and assumes that allele and geno-
type frequencies can be estimated. If the frequencies 
of the measured genotypes significantly differed from 
the HWE assumptions, genotyping errors among other 
possible factors, such as ethnic diversity and high levels 
of consanguinity in the population, are indicated leading 
to excluding the SNPs from further analyses. Association 
with p<0.05 were reported, indicating the replication of 
previously reported associations.
Statistical analyses for all clinical and laboratory vari-
ables were performed using Stata software V.14 . For 
continuous data, statistical differences were assessed 
using two-sided t-tests for normally distributed data or 
the Wilcoxon rank-sum (Mann-Whitney) test for highly 
skewed data. The Pearson χ2 test was used for percentage 
data as well as the Fisher’s exact test when the expected 
frequencies were less than 5. A p value<0.05 was consid-
ered as significant. PLINK software was also used for 
testing the associations between the SNPs and DKD 
using a case–control logistic regression model, which 
included age, gender, hypertension status, T2DM dura-
tion and eGFR levels as covariates (table 1). The results 
are presented as p values (Padjusted<0.05) and ORs with 
corresponding 95% CIs. The same approach (patients 
with DKD vs patients without DKD) was adopted to test 
the associations between the possible risk factors and 
the development of the DKD (table 3). However, the 
logistic model, which included all the associated factors 
listed in table 4 was validated by the Hosmer-Lemeshow 
goodness of fit test (p=0.11) to allow for the inclusion 
of several covariates. Analyses between SNPs and renal 
function traits were conducted in PLINK using linear 
regression models that included age and gender as 
covariates. The results were presented as beta coeffi-
cients (regression coefficients for the linear regression 
model, calculated based on the minor allele), standard 
errors and p values.
As this was a replication study, we reported all p 
values <0.05, suggesting possible replications. However, 
using a Bonferroni correction for multiple testing, the 
p values of some of the models with statistically signifi-
cant associations included p<0.00079 for the DKD asso-
ciations, p<0.0006 for the ACR, p<0.0005 for the vitamin 
D, p<0.00017 for the eGFR, p<0.00019 for the creatinine 
and p<0.00068 for associations with urea.
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statistical power considerations
The current study had a power ~57%. This is based on the 
current sample size (145 with DKD vs 265 without DKD), 
prevalence of DKD ~20% (depending on reference #2), 
genotype risk (OR)=1.5, significance level of 0.0008 
(following the correction of multiple testing using the 
Bonferroni correction), disease allele frequency=0.5 and 
multiplicative model. Calculations were verified using the 
Genetic Association Study Power Calculator (http:// csg. 
sph. umich. edu// abecasis/ cats/ gas_ power_ calculator/ 
index. html).
ethical considerations
Each patient agreed to take part in this study and 
provided an informed signed consent after a brief session 
to explain the aims and methods. The study conformed 
to the ethical principles outlined in the Declaration of 
Helsinki.
results
baseline data of kidney function associated traits and snPs 
selection
Of the 490 patients with T2DM that were recruited for 
this study, 115 patients were tested for genetic associa-
tions with the albumin-to-creatinine ratio, 328 for vitamin 
D levels (measured as 25-OH cholecalciferol), 395 for 
eGFR levels, 474 for serum creatinine levels and 450 for 
blood urea levels. Among the 490 patients, 410 had clear 
classifications for the diagnosis of kidney disease (145 
patients with DKD and 265 without DKD) according to 
the adopted diagnostic criteria (references #33 and #34) 
and/or patient medical records. The possible covariates 
that may affect the genetic associations for trait analyses 
are summarised in table 1.
Clinical and laboratory characteristics of patients with and 
without dKd
Both patient groups (with or without kidney disease) had 
poor glycaemic control with blood glucose levels above 
8 mmol/L. A comparison of patients with DKD to those 
without DKD indicated that the majority of patients with 
DKD were men (52% vs 38% for controls), older in age 
(67 vs 59 years), had significant rates of comorbidities, 
such as hypertension and dyslipidaemia, and had a longer 
T2DM duration (16 vs 10 years). A clear decline in renal 
function indices was also observed in patients with DKD 
compared with those without DKD, as indicated by the 
significantly higher rates of ACR, urea and creatinine, 
and significantly lower eGFR (table 2). However, patients 
with DKD tended to have lower low-density lipopro-
tein-cholesterol results as compared with those without 
DKD, which suggests that these patients were more likely 
to have received intensive statin therapy (table 2).
Factors associated with developing dKd in emirati patients 
with t2dM
Table 3 shows that T2DM duration was the single factor 
that significantly contributed to the development of DKD. 
Increased risk for DKD was significantly associated with 
the increasing duration of T2DM, cumulatively, up to 
20 years of duration. At a T2DM duration ≥20 years, the 
DKD risk stabilised at approximately 3.12 times higher as 
compared with patients with duration ≤5 years (p=0.02, 
95% CI 1.21 to 8.02). Although the levels of serum creat-
inine indicated a significant difference between no DKD 
and DKD patients (p=0.03), the OR of 1.03 showed no 
increased risk (table 3).
Genetic associations of renal function associated traits in 
emirati patients
The results of genetic associations for each tested renal 
function trait are shown in table 4. In summary, no asso-
ciation passed the Bonferroni correction for multiple 
testing. However, we report here the most suggestive asso-
ciations which point to replications of previous reports.
For blood urea, the best observed association was with 
rs11868441 in breast carcinoma-amplified sequence 
3  (BCAS3) (effect size: −0.038 log per allele A, p=0.014), 
followed by multiple SNPs in the R-Spondin 3 (RSPO3) 
gene.
For serum creatinine, two SNPs (rs6999484 and 
rs1705699) in the intergenic region between STC1 and 
ADAM28 showed the best associations with similar effect 
sizes (0.03 log per one copy of the corresponding minor 
Table 3 Risk factors for the development of kidney disease 
in patients with T2DM from the UAE
Covariate OR 95% CI P values
Age 0.99 0.96 to 1.04 0.80
Gender 0.90 0.34 to 2.36 0.83
BMI 1.02 0.97 to 1.08 0.49
Hypertension 2.00 0.60 to 6.74 0.26
HbA1c 0.86 0.69 to 1.07 0.19
Cholesterol 0.59 0.19 to 1.76 0.34
Triglyceride 1.09 0.62 to 1.94 0.76
HDL-cholesterol 1.25 0.64 to 2.45 0.52
LDL-cholesterol 1.38 0.42 to 4.57 0.60
Smoking history 0.80 0.34 to 1.87 0.61
Creatinine 1.03 1.00 to 1.06 0.03
Urea 1.13 0.92 to 1.38 0.26
eGFR 0.97 0.94 to 1.00 0.09
Diabetes 
duration (years)*
5–10 0.75 0.26 to 2.16 0.59
11–15 1.49 0.56 to 3.91 0.42
16–20 3.35 1.22 to 9.23 0.02
>20 3.12 1.21 to 8.02 0.02
*Diabetes duration reference is duration ≤5 years
BMI, body mass index; eGFR, estimated glomerular filtration rate; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; T2DM, 
type 2 diabetes mellitus; UAE, United Arab Emirates.
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allele), followed by SNP rs2828785 (p=0.008, effect 
size=−0.030 log per one copy of allele A), which is located 
in the non-coding gene area on chromosome 21. In addi-
tion, multiple genetic areas were also indicated, although 
with less significant associations.
eGFR levels were significantly associated with SNPs 
within the MED1 gene, rs2168785 with effect size of −4.299 
per allele G and rs12452509 with effect size of −4.232 per 
allele G and p=0.015 and 0.017, respectively. In addition, 
the SNPs in two genetic regions, WDR72 and SHROOM3, 
which are associated with serum creatinine levels, were 
also associated with eGFR levels, indicating a strong link 
to renal function.
Vitamin D levels were associated with three genetic 
regions including rs1801725 in CARS (effect size: 
−6.923 per allele A, p=0.0078), rs1155563 in GC (effect 
size: −6.951, p=0.0081) and two SNPs, rs12794714 and 
rs10500804, in cytochrome P450 family 2 subfamily R 
member 1 (CYP2R1) with effect sizes of approximately 
−5.0 and p values of 0.015 and 0.016, respectively.
One SNP, rs4528660, which is located in the intergenic 
region between LPIN2 and MYOM1 (effect size: −0.323 
log per allele A, p=0.027) was strongly associated with the 
albumin-to-creatinine ratio.
These data demonstrated that renal function traits are 
linked to several loci in the UAE population and that 
some loci (eg, WDR27 and SHROOM3) are linked to more 
than one trait.
Genetic associations of dKd in emirati patients
Sixty-three SNPs in 43 genetic loci, which have previ-
ously been linked to CKD or DKD, were included in our 
genetic analyses of DKD (145 patients with DKD versus 
265 without DKD). A logistic regression model including 
Table 4 Results of genetic association analyses of different renal function indices
SNP Chr: BP Gene A1/A2* MAF_% Beta† SE P value
Blood urea
rs11868441 17: 59239221 BCAS3 A/G 30.1 −0.038 0.015 0.014
rs1892172 6: 127476516 RSPO3 T/C 46.9 0.031 0.014 0.028
rs4644087 6: 127481154 RSPO3 C/A 46.8 0.030 0.014 0.03
rs4382293 6: 127475433 RSPO3 G/A 47.0 0.030 0.014 0.03
rs2489629 6: 127476717 RSPO3 G/A 44.9 −0.029 0.014 0.039
Serum creatinine
rs6999484 8: 23728271  STC1-ADAM28 A/G 23.8 0.033 0.011 0.003
rs1705699 8: 23781453 STC1-ADAM28 G/A 24.2 0.031 0.011 0.005
rs2828785 21: 25437505 - A/G 19.9 −0.030 0.011 0.008
rs11227279 11: 65495211 KRT8P26-AP5B1 A/G 28.4 −0.024 0.010 0.019
rs7785065 7: 32915204 KBTBD2 A/C 43.5 0.022 0.010 0.022
rs4859682 4: 77410318 SHROOM3 A/C 25.7 0.021 0.010 0.034
rs1031755 15: 53951435 WDR72 C/A 11.7 −0.029 0.014 0.038
rs7740534 6: 25077179 - C/A 9.6 −0.032 0.015 0.042
Estimated glomerular 
filtration rate
rs2168785 17: 37407135 MED1 G/A 28.2 −4.299 1.754 0.015
rs12452509 17: 37574722 MED1 G/A 28.1 −4.232 1.757 0.017
rs4776168 15: 53936907 WDR72 G/A 10.8 5.828 2.699 0.031
rs10518733 15: 53940307 WDR72 C/A 10.8 5.828 2.699 0.031
rs7541937 1: 35341982 DLGAP3 C/A 44.0 3.590 1.693 0.035
rs10032549 4: 77398015 SHROOM3 G/A 32.2 −3.655 1.750 0.037
rs2484639 1: 243462367 SDCCAG8 A/G 43.5 3.378 1.656 0.042
Vitamin D(25-OH 
cholecalciferol)
rs1801725 3: 122003757 CASR A/C 22.6 −6.923 2.584 0.008
rs1155563 4: 72643488 GC G/A 18.9 −6.951 2.608 0.008
rs12794714 11: 14913575 CYP2R1 A/G 41.5 −5.110 2.099 0.015
rs10500804 11: 14910273 CYP2R1 C/A 42.2 −5.004 2.060 0.016
Albumin:creatinine ratio
rs4528660 18: 3043516 LPIN2-MYOM1 G/A 17.8 −0.323 0.144 0.027
*A1/A2: minor to major alleles.
†Beta: regression coefficient for the linear regression model, calculated based on A1 (the minor allele).
BP, base pair position; Chr, chromosome; MAF, minor allele frequency; SNP, single nucleotide polymorphism.
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five possible covariates that may affect the development 
of kidney disease was applied (table 1). As depicted in 
table 5, the unadjusted analyses indicates two associations 
in CPS1 (rs7422339, p=0.019) and SHROOM3 (rs4859682, 
p=0.024), respectively. Following the adjustment for 
possible covariates, only the SHROOM3 rs4859682 
remained significant (p=0.04, OR=1.46). This confirms 
that SHROOM3 is a string risk locus for DKD, considering 
similar associations with serum creatinine and eGFR 
levels.
dIsCussIOn
A combination of environmental and clinical factors in 
genetically predisposed individuals have been suggested 
to be involved in DKD, including persistent hypergly-
caemia, arterial hypertension and/or dyslipidaemia.37 In 
addition, familial aggregation of nephropathy in T2DM 
has been reported in several populations.38 Therefore, 
understanding the complex multifactorial interactions 
between genetic, clinical and traditional kidney disease 
risk factors can provide insight into novel drugs and 
treatment strategies for DKD towards reducing the like-
lihood of developing ESRD. In this study, we investigated 
whether the genetic markers that correspond to DKD and 
renal function traits reported for different populations 
are similar to the Arab population.
The current Emirati population sample indicated that 
most patients with T2DM who developed DKD were males, 
about 10 years older, had more frequent comorbidities, 
specifically hypertension and showed a marked decline 
in their renal function profiles, as compared with those 
who did not develop the disease. However, patients with 
T2DM who did not develop DKD still had higher rates 
of comorbidities and poor diabetic control, in agreement 
with our previous results.29 We also found that the dura-
tion of diabetes was the single factor that significantly 
contributed to the development of kidney disease. Specif-
ically, the risk of developing DKD became significant 
when the duration of T2DM reached the 15-year mark. 
This is in alignment with previous reports, which suggest 
that patients with T2DM who do not develop signs of 
kidney disease by 15 years’ duration of diabetes seem to 
be protected, most likely due to genetic factors.39
The most notable finding of this study was the associa-
tion of shroom family member 3 (SHROOM3) with serum 
creatinine, eGFR and DKD. The minor allele for the 
SNP rs4859682 (A) was observed to increase the serum 
creatinine (0.021 log increase per one copy) and also to 
increase the risk for DKD (OR=1.46). SHROOM3 was first 
reported to be associated with eGFR levels in patients with 
DKD,13 then with serum creatinine40 and serum magne-
sium levels.41 This association was further replicated in 
different ethnicities.19 42 The SHROOM3 gene product is 
expressed in the human kidney and is reported to play an 
important role in epithelial cell shape regulation,43 as well 
as the maintenance of the glomerular filtration barrier 
integrity.44 Defective Shroom3 protein leads to decreased 
actin organisation and affects the mechanical character-
istics and integrity of the glomerular podocyte resulting 
in thinning of the glomerular filtration membrane.44 
Additionally, Shroom3 heterozygous (Shroom3Gt/+) mice 
showed developmental irregularities that manifested 
as adult-onset glomerulosclerosis and proteinuria.45 
Furthermore, genetic variants (such as the intronic 
variant rs17319721) were found to contribute to kidney 
allograft injury and the development of fibrosis through 
a mechanism involving transforming growth factor beta 
(TGF-β) signalling.46 Although the variant rs17319721 
was not found in our dataset, it is highly linked to the 
SNP rs4859682 (r2=0.85, D′=1), which was reported in this 
study to increase the risk for DKD and affect the levels of 
serum creatinine. Overall, this suggests that SHROOM3 
may be considered as a multiethnic risk gene for DKD 
and associated kidney function traits in various popula-
tions, including the Arabs who inhabit the UAE.
Similarly, the two loci, WD repeat domain 72 (WDR72), 
associated with eGFR and serum creatinine levels), and 
BCAS3, associated with blood urea levels), are also well-
known transethnic renal function traits loci.47 WDR72, in 
particular, has been well studied in association with kidney 
function traits and pathologies. For instance, WDR72 has 
been reported to be associated with creatinine produc-
tion or secretion,48 as well as signal transduction, cell cycle 
regulation and vesicular trafficking that affects podocyte 
activity, reduced eGFR and progression of CKD.49 In addi-
tion, RSPO3 has been previously reported to be associated 
with blood urea nitrogen concentration, in line with the 
results of the current study.42 The association of rs4528660 
near MYOM1 (Myomesin 1) with the albumin-to-creati-
nine ratio is also in agreement with previous work, which 
links this locus to albuminuria in patients with diabetes.50 
The current analyses also replicated the associations of 
calcium-sensing receptor (CASR), group-specific compo-
nent (GC) (vitamin D-binding protein, also known 
Table 5 Association between SNPs linked to CKD and DKD patients from the UAE
SNP Chr: BP Gene A1/A2*
MAF
Punadjusted Padjusted OR (95% CI)DKD (n=145) No DKD (n=265)
rs7422339 2: 211540507 CPS1 A/C 35.8% 27.9% 0.019 0.20 1.25 (0.89 to 1.75)
rs4859682 4: 77410318 SHROOM3 A/C 29.0% 21.9% 0.024 0.04 1.46 (1.01 to 2.10)
*A1/A2: minor to major alleles.
BP, base pair position; Chr, chromosome; CKD, chronic kidney disease; CPS1, carbamoyl-phosphate synthase; DKD, diabetic kidney disease; MAF, minor allele 
frequency; SHROOM3, shroom family member 3; SNPs, single nucleotide polymorphisms; UAE, United Arab Emirates.
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as GC-globulin) and  CYP2R1 with levels of vitamin 
D.51 These genes encode proteins that are involved in 
vitamin D function, including activation by hydroxyl-
ation (CYP2R1), transportation (GC) and serum calcium 
level sensoring (CASR).51 They have also been associated 
with calcium–vitamin D physiology and pathology, such 
as serum calcium levels, familial hypocalciuric hypercal-
caemia, tertiary hyperparathyroidism and vitamin D defi-
ciency presenting as rickets (see OMIM entries: CARS: 
601199; CYP2R1: 608713; and GC: 139200). For instance, 
CASR protein is expressed in the kidney among other 
tissue and regulates ion metabolism including calcium 
and magnesium. Mutations in CASR lead to abnormali-
ties in the regulation of the parathyroid gland and renal 
function causing hypercalcaemia and increased blood 
pressure, which in turn may affect kidney function.52 
Similarly, GC proteins bind actin and work as actin scav-
engers (as such GC may play a role in podocyte integrity), 
as well as a binding site for vitamin D. The GC protein is 
the precursor to the Gc-macrophage activating factor, a 
macrophage activator and suggests, together with vitamin 
D, that GC has an important role in the immune function 
and pathogenesis of CKD.53 Vitamin D is hydroxylated 
at the C25 position by specific hydroxylase coded by the 
CYP2R1 gene to 25-hydroxyvitamin D, which is the main 
circulating form of vitamin D. The low levels of vitamin D 
observed in CKD, due to reduced CYP2R1 production by 
the liver or due to a mutation in the gene, disturb calcium 
balance and lead to hyperparathyroidism. Conversely, 
the loss of renal protection caused by vitamin D and the 
increase in the renin–angiotensin pathway leads to hyper-
tension that further advances kidney disease.54 Further-
more, these genes have recently been shown to influence 
the outcome of vitamin D3 supplementation which, in the 
Arab context, is an important finding of our study.55
In summary, this work presents the first study to inves-
tigate the clinical and genetic factors influencing kidney 
function traits and DKD in a population of Arab ancestry. 
The results demonstrate that the duration of T2DM is 
the single most important risk factor for DKD devel-
opment in patients with T2DM in the UAE. Our study 
highlights that several genetic loci, which have been 
previously linked to renal function associated traits, 
are shared between diverse ethnic groups. As such, we 
have replicated previous findings of the association of 
SHROOM3 with DKD. The logistic analyses performed 
here did not include treatment modalities since most 
of the patients had multiple conditions and under-
went multiple treatments, which makes logistic regres-
sion largely unstable and difficult to interpret. A larger 
population sample across the Middle East is now being 
considered to confirm the extent of the shared genetic 
predisposition reported in the current study. Consid-
ering the high prevalence of T2DM in this population 
and the recent evidence of genomic structure variations 
among different ethnic groups, more genetic-driven 
population studies are warranted towards effective genet-
ically guided personalised medicine.
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